Clinical Trial Update: Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sipuleucel-T in combination with stereotactic ablative body radiation (SABR) for metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Metastatic Castrate-resistant Prostate Cancer, mCRPC | Phase 2 | Status: COMPLETED | Results posted: 2022-05-06